Drug Trial Radar · NCT05433272
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,400
Planned (sponsor's estimate)
Start
Aug 10, 2023
Primary completion
Sep 10, 2023
Study completion Sep 10, 2023
Sponsor
- Lead sponsor
- Sinovac Biotech (Colombia) S.A.S.Industry
- Sponsor type
- Industry
- Collaborators
- Sinovac Life Sciences Co., Ltd.
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain in healthy people aged 3 years old and above and have completed two or three doses of CoronaVac® in Colombia.
Conditions
- COVID-19
Interventions
Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron StrainBiological
The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
COVID-19 Vaccine (Vero Cell), InactivatedBiological
The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titer (GMT) of the neutralizing antibody to SARS-CoV-2 Delta strain and Omicron strainTime frame: At 14 days after one booster dose
- Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Delta strain and Omicron strainTime frame: At 14 days after one booster dose
- GMT of the neutralizing antibody to SARS-CoV-2 Prototype strainTime frame: At 14 days after one booster dose
- Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Prototype strainTime frame: At 14 days after one booster dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinica de la Costa
Barranquilla, Colombia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.